Health Care

Documents show the Food and Drug Administration took 684 days to issue a warning letter after uncovering serious issues at the pharmacy at the center of the recent U.S. meningitis outbreak.

Merck upped its quarterly dividend by a penny to 43 cents per share Tuesday, citing optimism about the future. 

AstraZeneca agreed to buy Bristol-Myers Squibb’s (NYSE:BMY) stake in their diabetes joint venture for up to $4.1 billion.

AstraZeneca agreed to buy Bristol-Myers Squibb’s (NYSE:BMY) stake in their diabetes joint venture for up to $4.1 billion.

Rite Aid revealed slightly higher third-quarter sales on Thursday but axed its outlook.  

CVS Caremark and Cardinal Health crafted a deal to form the largest generic drug sourcing operation in the U.S.

UnitedHealth Group unveiled earnings and revenue projections for 2014 that missed Wall Street’s expectations.

The $2.1 billion acquisition of Apria's Coram is aimed at bolstering CVS Caremark's specialty pharmacy business. 

While a battle rages over technical issues on the ACA site, questions are emerging about the safety of data entered into its systems.

J&J has reportedly reached a $4 billion settlement to resolve thousands of lawsuits stemming from a 2010 hip implant recall.

European drug maker Shire reached a $4.2 billion deal on Monday to acquire U.S. rare disease drug maker ViroPharma.

The drug store chain posted higher quarterly profit and raised its forecast for the year after strong prescriptions sales.

Boston Scientific announced plans on Wednesday to axe up to 1,500 positions and expects to report softer-than-expected revenue for the full year.

Bristol-Myers Squibb reported better-than-expected quarterly earnings, fueled by strong sales of cancer and diabetes drugs.

Travelers reported a 3Q profit beating expectations, and a $5 billion buyback program, sending its shares up 3% pre-market.

Nestle reportedly spoke to a small group of potential buyers to sell the diet business, as it looks to divest underperforming units.

German drug distributor Celesio is reportedly in advanced talks about being acquired by U.S. rival McKesson for $5.08 billion.

The No. 1 U.S. drug-store operator benefited from stronger pharmacy sales and increased cost synergies.

AstraZeneca scooped up privately held Amplimmune for about half-a-billion dollars as it looks to strengthen its pipeline of cancer drugs.

No one said that overhauling healthcare, which accounts for 17% of all national spending, was going to happen with a skeleton crew.